Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer;Signification clinique, diagnostique et intérêt théranostique des mutations du gène PIK3CA dans le cancer du sein

Bulletin du Cancer

Volumn 100, Issue 10, 2013, Pages 947-954

  Harlé, Alexandre ^a,b,c   Lion, Maëva ^a,b,c   Lozano, Nicolas ^a   Merlin, Jean Louis ^a,b,c  

^a Service d'anatomie pathologique Institut de cancérologie de Lorraine   (France)

^b CENTRE DE RECHERCHE EN AUTOMATIQUE DE NANCY   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Breast cancer; Molecular diagnostics; PI3Kinase; PIK3CA; Theranostics

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RESISTANCE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY;

EID: 84886844284     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2013.1827     Document Type: Article

References (48)

1. INCa. La situation du cancer en France en 2011. In: Observation des cancers. Paris, France: INCa, 2011 (p. 40-41).
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
3. Tokunaga E, Oki E, Egashira A, et al. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008; 8: 27-36.
4. Dunlap J, Le C, Shukla A. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 2009; 120: 409-18.
5. Aleskandarany MA, Rakha EA, Ahmed MA, et al. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat 2009; 122: 45-53.
6. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006; 94: 455-9.
7. Perez-Tenorio G, Alkhori L, Olsson B, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007; 13: 3577-84.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
9. Cavalli F, Alberto P, Jungi F, Brunner K, Martz G. Hormonochemotherapy versus hormonotherapy followed by chemotherapy in the treatment of disseminated breast cancer. Eur J Cancer 1980; (Suppl 1): 125-9.
10. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-19.
11. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43.
12. Baselga J. Treatment of HER2-overexpressing breast cancer. Ann Oncol 2010; 21: vii36-40.
13. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008; 26: 5544-52.
14. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-91.
15. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-9.
16. Wong AL, Lee SC. Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int J Breast Cancer 2012; 2012: 9.
17. Razis E, Bobos M, Kotoula V, et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast 2011; 128: 447-56.
18. Dumont AG, Dumont SN, Trent JC. The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. Chin J Cancer 2012; 31: 327-34.
19. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17-23.
20. Esteva FJ, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and pp70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010; 177: 1647-56.
21. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009; 102: 19-65.
22. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-19.
23. Shull AY, Latham-Schwark A, Ramasamy P, et al. Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One 2012; 7: 17.
24. Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011; 1: 170-85.
25. Robert J. Signalisation cellulaire et cancer. Paris, France: Springer- Verlag, 2010.
26. Bellacosa A, Kumar CC, Di Cristofano A, Testa Jr. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005; 94: 29-86.
27. Miron A, Varadi M, Carrasco D, et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 2010; 70: 5674-8.
28. Moskalev EA, Stohr R, Rieker R, et al. Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing. Virchows Arch 2013; 462: 409-19.
29. Baker CL, Vaughn CP, Samowitz WS. A PIK3CA pyrosequencingbased assay that excludes pseudogene interference. J Mol Diagn 2012; 14: 56-60.
30. Vorkas PA, Poumpouridou N, Agelaki S, Kroupis C, Georgoulias V, Lianidou ES. PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. J Mol Diagn 2010; 12: 697-704.
31. Harle A, Lion M, Lozano N, et al. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCRARMS: Correlation with clinicopathological criteria. Oncol Rep 2013; 29: 1043-52.
32. Board RE, Thelwell NJ, Ravetto PF, et al. Multiplexed assays for detection of mutations in PIK3CA. Clin Chem 2008; 54: 757-60.
33. Spoerke JM, O'Brien C, Huw L, et al. Phosphoinositide 3-Kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 2012; 18: 6771-83.
34. Trigka EA, Levidou G, Saetta AA, et al. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncol 2013; 30: 623-36.
35. Guiu S, Michiels S, Andre F, et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 2012; 23: 2997-3006.
36. Sorlie T. Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol Biol 2007; 360: 91-114.
37. Lerma E, Catasus L, Gallardo A, et al. Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. Virchows Arch 2008; 453: 133-9.
38. Cizkova M, Susini A, Vacher S, et al. PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2- based subgroups. Breast Cancer Res 2012; 14: R28.
39. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-65.
40. Haque R, Ahmed SA, Inzhakova G, et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev 2012; 21: 1848-55.
41. Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Friedecky D, HajduchM. Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154: 281-8.
42. Ellis MJ, Lin L, Crowder R, et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 2010; 119: 379-90.
43. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3- Kinase and Antiestrogen Resistance in Breast Cancer. J Clin Oncol 2011; 2011: 17.
44. Sartore-Bianchi A, Bencardino K, Cassingena A, et al. Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer 2010; 36: S1-5.
45. Loi S, Michiels S, Baselga J, et al. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS One 2011; 8: 2.
46. Meric-Bernstam F, Akcakanat A, Chen H, et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 2012; 18: 1777-89.
47. Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011; 30: 3222-33.
48. Wallin JJ, Edgar KA, Guan J, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011; 10: 2426-36.